Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MD
MD logo

MD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
21.120
Open
20.790
VWAP
20.91
Vol
41.48K
Mkt Cap
1.72B
Low
20.750
Amount
867.17K
EV/EBITDA(TTM)
7.20
Total Shares
83.00M
EV
1.82B
EV/OCF(TTM)
6.62
P/S(TTM)
0.92
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Show More

Events Timeline

(ET)
2026-02-19
06:20:00
Pediatrix Medical Sees FY26 Adjusted EBITDA of $280M-$300M
select
2026-02-19
06:20:00
Pediatrix Medical Group Reports Q4 Revenue of $494M
select
2025-11-03 (ET)
2025-11-03
06:06:06
Pediatrix Medical increases FY25 adjusted EBITDA forecast to a range of $270M-$290M.
select
2025-11-03
06:05:04
Pediatrix Medical announces Q3 adjusted EPS of 67 cents, surpassing consensus estimate of 47 cents.
select

News

Newsfilter
5.0
03-24Newsfilter
Pediatrix Appoints Two Quality Care Experts
  • Executive Appointments: Pediatrix Medical Group has announced the appointment of Dr. James Barry as Chief Clinical Quality & Transformation Officer and Dr. Jochen Profit as Chief Quality Advisor, both renowned for their expertise in care quality, which is expected to enhance the company's service quality for women, babies, and children.
  • Quality Improvement Strategy: Dr. Barry will be responsible for shaping the medical direction of the organization, ensuring the highest standards of patient care, and overseeing the work of the Pediatrix Center for Research, Education, Quality and Safety, aimed at improving patient experience and reducing healthcare costs through clinical research and continuous quality improvement.
  • Innovation and Leadership: Dr. Barry's contributions in neonatal critical care and medical artificial intelligence will provide strategic advantages for Pediatrix, as his experience will help the company maintain competitiveness in a rapidly evolving healthcare environment.
  • Research and Optimization: Dr. Profit's research on optimizing care delivery for pregnant individuals and newborns will provide expert guidance for Pediatrix, advancing the company's efforts in health equity and family-centered care, thereby enhancing patient safety and care quality.
Newsfilter
1.0
02-23Newsfilter
Pediatrix Hosts 47th Annual Neonatology Conference
  • Neonatology Conference: Pediatrix Medical Group is hosting the 47th Annual NEO Conference from February 25-27 in Las Vegas, bringing together leading experts to discuss the latest research and innovations in neonatal medicine aimed at improving newborn care outcomes.
  • Preterm Birth Rates: The March of Dimes' 2025 Report Card indicates that the national preterm birth rate remains at 10.4%, meaning one in ten newborns is born prematurely, underscoring the ongoing need for innovation in neonatal-perinatal medicine.
  • Continuing Education Opportunities: Attendees can earn up to 20 AMA PRA Category 1 Credits and 20 nursing contact hours, reflecting Pediatrix's commitment to enhancing the skills and knowledge of healthcare professionals in the field.
  • Hall of Fame Induction: During the conference, Dr. Waldemar Carlo will be inducted into the Legends of Neonatology Hall of Fame, recognizing his pioneering research in neonatal resuscitation and global health initiatives, further advancing neonatal care practices.
seekingalpha
9.5
02-19seekingalpha
Pediatrix Medical Group Q4 2025 Earnings Call Highlights
  • Strong Financial Performance: Pediatrix Medical Group reported an adjusted EBITDA of $66 million for Q4 2025, consistent with upwardly adjusted guidance, reflecting robust business volume, acuity, and payer mix, which underscores effective financial control within the organization.
  • New Incentive Programs: The introduction of a stock price performance-linked bonus program and the Pediatrix Partners leadership group, comprising 46 physicians receiving stock tracking grants, aims to enhance organizational cohesion and clinical leadership, aligning with the company's strategic objectives.
  • 2026 Outlook: Management projects adjusted EBITDA for 2026 to be between $280 million and $300 million, indicating a 5% growth at the midpoint compared to 2025, while anticipating flat revenue, which reflects a cautious approach to market conditions.
  • Cash Flow and Share Repurchase: The company generated $115 million in operating cash flow in Q4, down from the previous year, and repurchased 2.9 million shares during the quarter, reducing outstanding shares to approximately 83 million, demonstrating a disciplined approach to capital allocation.
Fool
9.5
02-19Fool
Pediatrix Medical Group Shares Plunge 12% Following Earnings Report
  • Disappointing Earnings: Pediatrix Medical Group reported fourth-quarter revenue of nearly $493.8 million, down almost 2% year-over-year, indicating pressure in the competitive healthcare services market, despite analysts' expectations of $486.2 million.
  • Declining Net Income: The company's non-GAAP net income fell to $42.5 million ($0.50 per share), down from $43.5 million a year ago, reflecting challenges in cost control amid rising operational expenses.
  • Increased Bonus Payouts: The tightening labor market for healthcare professionals led to significantly higher bonus payouts, negatively impacting the company's bottom line and raising investor concerns about future profitability.
  • Cautious Future Outlook: Pediatrix anticipates adjusted EBITDA of $280 million to $300 million for full-year 2026, which, while an increase from last year's $275.6 million, still reflects analysts' tepid growth expectations, contributing to diminished market confidence.
Newsfilter
9.5
02-19Newsfilter
Pediatrix Medical Group Reports Q4 2025 Earnings Results
  • Financial Performance Overview: Pediatrix Medical Group reported net revenue of $494 million and net income of $34 million for Q4 2025, with an adjusted EPS of $0.50, indicating stable operational capacity despite a slight decline in revenue compared to the previous year, aligning with the company's upwardly revised expectations.
  • Same-Unit Revenue Growth: The same-unit revenue increased by 4.0% in Q4 2025, primarily driven by improved collection activities and higher patient acuity, although patient service volumes decreased by 2.7%, demonstrating resilience in market demand, particularly in hospital-based services.
  • Cost Control and Adjustments: Operating expenses for Q4 were $444 million, down from $463 million in the prior year, mainly due to the impact of practice dispositions, despite rising clinical compensation costs, reflecting the company's efforts in cost management.
  • Future Outlook: Pediatrix anticipates its 2026 adjusted EBITDA to range between $280 million and $300 million, showcasing confidence in future growth, particularly as the company continues to invest in innovation and service quality amid challenges in the healthcare industry.
seekingalpha
9.5
02-19seekingalpha
Pediatrix Medical Group Q4 Earnings Analysis
  • Earnings Performance: Pediatrix Medical Group reported a Q4 non-GAAP EPS of $0.50, missing estimates by $0.04, indicating pressure on profitability that may affect investor confidence.
  • Revenue Trends: The company's Q4 revenue was $494 million, a 1.6% year-over-year decline, although it beat market expectations by $7.77 million, reflecting challenges faced by the business, particularly from practice dispositions.
  • Net Revenue Analysis: For the three months ending December 31, 2025, net revenue was $493.8 million, down from $502.4 million in the prior year, primarily due to the impact of non-same unit activity, indicating insufficient adaptability in the market.
  • Future Outlook: Pediatrix anticipates its 2026 Adjusted EBITDA to range between $280 million and $300 million, showing potential for growth despite challenges, which may provide a basis for future strategic adjustments.
Wall Street analysts forecast MD stock price to rise
3 Analyst Rating
Wall Street analysts forecast MD stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
23.00
Averages
23.50
High
24.00
Current: 0.000
sliders
Low
23.00
Averages
23.50
High
24.00
UBS
AJ Rice
Neutral
downgrade
$23 -> $22
AI Analysis
2026-02-24
Reason
UBS
AJ Rice
Price Target
$23 -> $22
AI Analysis
2026-02-24
downgrade
Neutral
Reason
UBS analyst AJ Rice lowered the firm's price target on Pediatrix Medical to $22 from $23 and keeps a Neutral rating on the shares. The ACA headwind remains a source of uncertainty, the analyst tells investors in a research note.
Deutsche Bank
Hold
downgrade
$21 -> $19
2026-02-20
Reason
Deutsche Bank
Price Target
$21 -> $19
2026-02-20
downgrade
Hold
Reason
Deutsche Bank lowered the firm's price target on Pediatrix Medical to $19 from $21 and keeps a Hold rating on the shares. The firm says the company's volumes were weaker than expected in Q4.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Pediatrix Medical Group Inc (MD.N) is 9.87, compared to its 5-year average forward P/E of 10.73. For a more detailed relative valuation and DCF analysis to assess Pediatrix Medical Group Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
10.73
Current PE
9.87
Overvalued PE
14.74
Undervalued PE
6.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.43
Current EV/EBITDA
6.97
Overvalued EV/EBITDA
10.64
Undervalued EV/EBITDA
6.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.74
Current PS
0.92
Overvalued PS
1.06
Undervalued PS
0.43

Financials

AI Analysis
Annual
Quarterly

Whales Holding MD

D
Dana Investment Advisors Inc
Holding
MD
-9.00%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Pediatrix Medical Group Inc (MD) stock price today?

The current price of MD is 20.855 USD — it has increased 0.51

What is Pediatrix Medical Group Inc (MD)'s business?

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

What is the price predicton of MD Stock?

Wall Street analysts forecast MD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is23.50 USD with a low forecast of 23.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pediatrix Medical Group Inc (MD)'s revenue for the last quarter?

Pediatrix Medical Group Inc revenue for the last quarter amounts to 493.77M USD, decreased -1.71

What is Pediatrix Medical Group Inc (MD)'s earnings per share (EPS) for the last quarter?

Pediatrix Medical Group Inc. EPS for the last quarter amounts to 0.40 USD, increased 11.11

How many employees does Pediatrix Medical Group Inc (MD). have?

Pediatrix Medical Group Inc (MD) has 2295 emplpoyees as of March 25 2026.

What is Pediatrix Medical Group Inc (MD) market cap?

Today MD has the market capitalization of 1.72B USD.